Knight Therapeutics Inc. (TSX: GUD)
Canada
· Delayed Price · Currency is CAD | Market Cap | 618.15M |
| Revenue (ttm) | 332.21M |
| Net Income (ttm) | -17.44M |
| Shares Out | 101.38M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | 263.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,252 |
| Open | 6.14 |
| Previous Close | 6.14 |
| Day's Range | 6.10 - 6.17 |
| 52-Week Range | 4.35 - 6.22 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | 7.19 (+17.68%) |
| Earnings Date | Aug 8, 2024 |
About Knight Therapeutics
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Ne... [Read more]
Financial Performance
In 2023, GUD's revenue was 328.20 million, an increase of 11.80% compared to the previous year's 293.56 million. Losses were -16.84 million, -43.68% less than in 2022.
Financial StatementsNews
Knight Therapeutics reports Q1 results
Knight Therapeutics Reports First Quarter 2024 Results
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial re...
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusi...
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the votin...
Notice of Knight Therapeutics’ First Quarter 2024 Results Conference Call
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financia...
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financi...
Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript
Knight Therapeutics GAAP EPS of -C$0.23, revenue of C$74.2M
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2023 Results Conference Call
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year e...
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year ...
Knight Therapeutics launches Minjuvi in Brazil
Knight Therapeutics Inc. Celebrates its First Decade of Success
MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year ann...
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit...
Knight Therapeutics Announces Launch of Bijuva® in Canada
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol ...
Amneal Pharma inks licensing pact with Knight Therapeutics
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada....
Knight Therapeutics Inc. (KHTRF) Q3 2023 Earnings Call Transcript
Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ETCompany ParticipantsSamira Sakhia - President and Chief...
Knight Therapeutics reports Q3 results
Knight Therapeutics reports Q3 earnings, with non-GAAP EPS of C$0.15 and revenue of C$0.08M.
Knight Therapeutics Reports Third Quarter 2023 Results
MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...
Notice of Knight Therapeutics’ Third Quarter 2023 Results Conference Call
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financi...
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financ...
Knight Therapeutics Inc. places No. 90 on The Globe and Mail’s fifth-annual ranking of Canada’s Top Growing Companies
MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top...
Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies
MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada's To...
Knight Therapeutics Reports Second Quarter 2023 Results
MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...